istaroxime
istaroxime: developed by 1 company · 1 clinical trial tracked.
istaroxime evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect istaroxime to WINT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could istaroxime → WINT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Cardiogenic Shock
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) Cardiogenic Shock | Phase 1/Phase 2 |
Clinical Trials (1)
A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C
Primary endpoint: SBP AUC 0-6
InterventionalRandomizedtriple20 targetStarted 2024-06Completion 2026-0815 sites · Argentina, Israel, Italy, Poland…Windtree Therapeutics
Frequently asked questions
Who is developing istaroxime?
istaroxime is being developed by WINDTREE THERAPEUTICS INC /DE/.
How many clinical trials involve istaroxime?
BioSniper tracks 1 clinical trial involving istaroxime.